ИСТИНА

Within the project, new contrast agents (CA) for eCT were developed, based on Ln-containing nanoparticles (La, Nd, Gd) stabilized on carbon nanomaterials and silicon dioxide. The primary objective of the first phase was to obtain stable nanocomposites with high contrast properties for their subsequent use in biomedical research. Nanocomposites based on few-layered graphite fragments (FLGF) and SiO2 were synthesized and their physicochemical properties were studied. These composites demonstrated the ability to precisely control particle size and morphology. Energy-sensitive CT using phantom studies showed that such contrast agents allow for accurate differentiation of high atomic number elements. Preliminary studies of the pharmacokinetics and toxicological profile of the contrast agents revealed the need for further optimization for in vivo applications. Ongoing work is focused on improving suspension stability and enhancing the sensitivity of the method.